Academic literature on the topic 'Publications on pneumonia'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Publications on pneumonia.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Publications on pneumonia"
1
Cirino, Luís Marcelo Inaco, Filumena Maria da Silva Gomes, and Bernardo Nogueira Batista. "The etiology of extensive pleural effusions with troublesome clinical course among children." Sao Paulo Medical Journal 122, no. 6 (2004): 269–72. http://dx.doi.org/10.1590/s1516-31802004000600008.
Full textAbstract:
CONTEXT: In São Paulo, pneumonia is the main infectious cause of death among children. Parapneumonic pleural effusion is a possible complication and has to be treated surgically when the patient does not respond to antibiotics. OBJECTIVE: Assessment of the etiology of complicated parapneumonic pleural effusions that needed surgical intervention. TYPE OF STUDY: Retrospective study. SETTING: University hospital of the University of São Paulo. METHOD: Analysis of 4,000 files on children hospitalized with pneumonia from November 1986 to November 1996 had shown that 115 of these children presented a total of 117 cases of pleural empyema that required surgical procedures. The children's clinical condition was assessed in relation to radiological findings and to their nutrition and immunization status. Previous antimicrobial therapy and pleural effusion bacterioscopy were also evaluated. RESULTS: Streptococcus pneumoniae was the agent found most commonly, as frequently in blood cultures as in pleural effusions. DISCUSSION: Data on vaccination coverage, birth weight and nutritional status are analyzed and compared to other publications. We observed that pleural effusion has a high potential for discomfort, and in most cases it is not a complication of the first pulmonary disease episode. Previous use of antibiotics interfered with culture positivity. The agent most frequently found was Streptococcus pneumoniae, which is in accordance with the findings from other authors. Nonetheless, the antibiotics used to treat the patients after the procedure were the same used in non-complicated pneumonias, which has led us to conclude that the worse outcome in this cases was not due to drug resistance. CONCLUSION: The bacteriological profile in our series of complicated pneumonia cases was similar to what has been described for non-complicated pneumonia cases. Future studies will be necessary to determine why these children presented a worse outcome.
2
Jia, Mingwang, Wenjie Huang, Li Li, Zhong Xu, and Lichan Wu. "Statins Reduce Mortality After Non-severe but Not After Severe Pneumonia: A Systematic Review and Meta-Analysis." Journal of Pharmacy & Pharmaceutical Sciences 18, no. 3 (2015): 286. http://dx.doi.org/10.18433/j34307.
Full textAbstract:
PURPOSE: The objective of this study was to perform a systematic review and meta-analysis of the effects of statins on mortality for patients with non-severe pneumonia or severe pneumonia. METHODS: PubMed, EMBASE, Cochrane Database of Systematic Reviews, Cochrane central register of controlled trials and Clinicaltrials.gov were searched for the association between statins and non-severe/severe pneumonia. Eligible articles were analyzed in Stata 12.0. RESULTS: The database search yielded a total of 566 potential publications, 24 studies involving 312,309 patients met the eligibility criteria. Pooled unadjusted data showed that statin use was associated with lower mortality after non-severe pneumonia (odds ratio [OR] 0.70, 95% confidence interval [CI], 0.66-0.73), but not severe pneumonia (OR 1.05; 95% CI, 0.86-1.28). However, this protective effect of statins was weakened using adjusted estimates (OR 0.78, 95% CI, 0.75-0.82). Besides, protective effect of statins was attenuated by confounders in a subgroup analysis, especially when accounting for pneumonia severity indicators (OR 0.88; 95% CI, 0.80-0.96). CONCLUSIONS: Statin use was associated with reduced mortality after non-severe pneumonia but not severe pneumonia and this protective effect was weakened in subgroups. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
3
Ghia, Canna J., Raja Dhar, Parvaiz A. Koul, Gautam Rambhad, and Mark A. Fletcher. "Streptococcus pneumoniae as a Cause of Community-Acquired Pneumonia in Indian Adolescents and Adults: A Systematic Review and Meta-Analysis." Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 13 (January 2019): 117954841986279. http://dx.doi.org/10.1177/1179548419862790.
Full textAbstract:
Background: Streptococcus pneumoniae is one of the primary cause of community-acquired pneumonia (CAP) worldwide. However, scant data are available on the prevalence of etiological organisms for CAP in adolescent and adult Indian population. Objective: We performed a systematic review and meta-analysis to determine the contribution of S. pneumoniae in the causation of CAP in Indian patients aged 12 years or above. Methodology: We performed a systematic search of both indexed and non-indexed publications using PubMed, databases of National Institute of Science Communication and Information Resources (NISCAIR), Annotated Bibliography of Indian Medicine (ABIM), Google Scholar, and hand search including cross-references using key terms ‘community acquired pneumonia AND India’. All studies, published between January 1990 and January 2017, that evaluated Indian patients aged above 12 years with a confirmed diagnosis of CAP were eligible for inclusion. Our search retrieved a total of 182 studies, of which only 17 and 12 qualified for inclusion in the systematic review of all etiological organisms, and meta-analysis of S. pneumonia, respectively. Results: A total of 1435 patients met the inclusion criteria. The pooled proportion of patients with S. pneumoniae infection was 19% (95% confidence interval [CI]: 12%-26%; I2 = 94.5% where I2 represents heterogeneity, P < .01). Other major etiological agents are Mycoplasma pneumoniae (15.5% [1.1%-35.5%]), Klebsiella pneumoniae (10.5% [1.6%-24.0%]), and Legionella pneumophila (7.3% [2.5%-23.8%]). Conclusions: Analysis found approximately a one-fifth proportion of adult Indian patients of CAP with S. pneumoniae infection, suggesting it as a leading organism for causing CAP compared with other etiological organisms.
4
Corrêa, Ricardo de Amorim, Andre Nathan Costa, Fernando Lundgren, et al. "2018 recommendations for the management of community acquired pneumonia." Jornal Brasileiro de Pneumologia 44, no. 5 (2018): 405–23. http://dx.doi.org/10.1590/s1806-37562018000000130.
Full textAbstract:
ABSTRACT Community-acquired pneumonia (CAP) is the leading cause of death worldwide. Despite the vast diversity of respiratory microbiota, Streptococcus pneumoniae remains the most prevalent pathogen among etiologic agents. Despite the significant decrease in the mortality rates for lower respiratory tract infections in recent decades, CAP ranks third as a cause of death in Brazil. Since the latest Guidelines on CAP from the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association) were published (2009), there have been major advances in the application of imaging tests, in etiologic investigation, in risk stratification at admission and prognostic score stratification, in the use of biomarkers, and in the recommendations for antibiotic therapy (and its duration) and prevention through vaccination. To review these topics, the SBPT Committee on Respiratory Infections summoned 13 members with recognized experience in CAP in Brazil who identified issues relevant to clinical practice that require updates given the publication of new epidemiological and scientific evidence. Twelve topics concerning diagnostic, prognostic, therapeutic, and preventive issues were developed. The topics were divided among the authors, who conducted a nonsystematic review of the literature, but giving priority to major publications in the specific areas, including original articles, review articles, and systematic reviews. All authors had the opportunity to review and comment on all questions, producing a single final document that was approved by consensus.
5
Morozov, S. P., D. Yu Kokina, N. A. Pavlov, Yu S. Kirpichev, V. A. Gombolevskiy, and A. E. Аndreychenko. "Clinical aspects of using artificial intelligence for the interpretation of chest X-rays." Tuberculosis and Lung Diseases 99, no. 4 (2021): 58–64. http://dx.doi.org/10.21292/2075-1230-2021-99-4-58-64.
Full textAbstract:
The review considers the possible use of artificial intelligence for the interpretation of chest X-rays by analyzing 45 publications. Experimental and commercial diagnostic systems for pulmonary tuberculosis, pneumonia, neoplasms and other diseases have been analyzed.
6
Naranjo, Olga Rajas, and Javier Aspa Marco. "Pneumonia Awareness Year, 2004: Scientific Impact Through Publications in Archivos de Bronconeumología." Archivos de Bronconeumología ((English Edition)) 42, no. 10 (2006): 541–52. http://dx.doi.org/10.1016/s1579-2129(06)60582-x.
Full text
7
Buda, Natalia, Wojciech Kosiak, Marcin Wełnicki, et al. "Recommendations for Lung Ultrasound in Internal Medicine." Diagnostics 10, no. 8 (2020): 597. http://dx.doi.org/10.3390/diagnostics10080597.
Full textAbstract:
A growing amount of evidence prompts us to update the first version of recommendations for lung ultrasound in internal medicine (POLLUS-IM) that was published in 2018. The recommendations were established in several stages, consisting of: literature review, assessment of literature data quality (with the application of QUADAS, QUADAS-2 and GRADE criteria) and expert evaluation carried out consistently with the modified Delphi method (three rounds of on-line discussions, followed by a secret ballot by the panel of experts after each completed discussion). Publications to be analyzed were selected from the following databases: Pubmed, Medline, OVID, and Embase. New reports published as of October 2019 were added to the existing POLLUS-IM database used for the original publication of 2018. Altogether, 528 publications were systematically reviewed, including 253 new reports published between September 2017 and October 2019. The new recommendations concern the following conditions and issues: pneumonia, heart failure, monitoring dialyzed patients’ hydration status, assessment of pleural effusion, pulmonary embolism and diaphragm function assessment. POLLUS-IM 2020 recommendations were established primarily for clinicians who utilize lung ultrasound in their everyday clinical work.
8
Nair, N. Sreekumaran, Leslie Edward Lewis, Theophilus Lakiang, Myron Godinho, Shruti Murthy, and Bhumika T. Venkatesh. "Factors associated with mortality due to neonatal pneumonia in India: a protocol for systematic review and planned meta-analysis." BMJ Open 7, no. 9 (2017): e017616. http://dx.doi.org/10.1136/bmjopen-2017-017616.
Full textAbstract:
IntroductionIndia contributes to the highest number of neonatal deaths globally. It also has the greatest number of pneumonia-related neonatal deaths in the developing world. We aim to systematically review the evidence for the factors associated with mortality due to neonatal pneumonia in the Indian context, to address the lack of consolidated evidence on this important issue.Methods and analysisThis protocol is part of a series of three reviews on neonatal pneumonia in India. Observational studies reporting on outcome of neonatal pneumonia in the Indian context, and published in English in peer-reviewed and indexed journals will be eligible for inclusion. Outcomes of this review will be the factors determining mortality due to neonatal pneumonia. A total of nine databases will be searched. Electronic and hand searching of published and grey literature will be performed. Selection of studies will be done in title, abstract and full text screening stages. Risk of bias, independently assessed by two authors, will be evaluated. Meta-analysis will be performed and heterogeneity assessed. Pooled effect estimates will be stated with 95% confidence intervals. Narrative synthesis will be done where meta-analysis cannot be performed. Publication bias will be evaluated and sensitivity analysis performed according to study quality. Quality of this review will be evaluated using AMSTAR (Assessing the Methodological quality of Systematic Reviews) and GRADE (Grades of Recommendation, Assessment, Development & Evaluation). A summary of findings table will be reported using GRADEPro.Ethics and disseminationSince this is a review involving analysis of secondary data which is available in the public domain, and does not involve human participants, ethical approval was not required. The findings of the study will be shared with all stakeholders of this research. Knowledge dissemination workshops will be conducted with relevant stakeholders to transfer the evidence, tailored to the stakeholder (eg, policy briefs, publications, information booklets, etc).
9
Stashkiv, V. I., K. A. Zamyatina, M. Yu Shantarevich, I. V. Nikitina, G. G. Kаrmаzаnovsky, and A. Sh Revishvili. "CT findings in patients with COVID-19 pneumonia after treatment with tocilizumab: foreign literature review." Medical Visualization 24, no. 2 (2020): 96–104. http://dx.doi.org/10.24835/1607-0763-2020-2-96-97.
Full textAbstract:
Purpose. Review and analysis of the available foreign literature about CT findings in patients with COVID-19 pneumonia after treatment with tocilizumab.Material and methods. 6 publications were analyzed that were available for the keywords “COVID-19”, “radiology”, “CT”, “tocilizumab”, “cytokine release syndrome”, “interleukin 6”, “IL-6”. Search was limited only to English language manuscripts with no time limit. The literature search was last done on 3rd June 2020.Results. There is a small number of studies on CT findings of COVID-19 pneumonia during the treatment of actemra (tocilizumab). At the request of “COVID-19”, “radiology”, “CT”, “tocilizumab”, “cytokine release syndrome”, “interleukin 6”, “IL-6” in the database of medical and biological publications “PubMed” on 03.06.2020 can be found only 8 publications that would satisfy the search query. At the time of writing this article we were able to locate only 1 full text articles in English which was the study of CT findings in patients with COVID-19 pneumonia after treatment with tocilizumab. It is important to note that new data is being shared regularly and so far, it consists mostly of pre-prints, case reports, small case series.Conclusion. After analyzing the available literature, it can be concluded that the majority of authors confirm the positive effect associated with taking tocilizumab, as evidenced by a very rapid improvement in the condition of patients, however, the CT-findings often does not correlate with the clinical course of the disease and does not always show improvement in lung tissue, which should not be regarded as negative dynamics, but as a natural regression of pathological changes in lung tissue.
10
Poda, Olha A., Tetyana O. Kryuchko, Inna N. Nesina, Olha Ya Tkachenko, and Nataliia V. Kuzmenko. "MODERN APPROACHES TO TREATMENT OF PSEUDOMONAS AERUGINOSA VENTILATOR-ASSOCIATED PNEUMONIA (LITERATURE REVIEW)." Wiadomości Lekarskie 72, no. 5 (2019): 892–96. http://dx.doi.org/10.36740/wlek201905130.
Full textAbstract:
Introduction: Nowadays anti-microbial therapy of ventilator-associated pneumonia caused by is one of the most topical issue as a consequence of widespread multiresistant strains of causative agent and their biological peculiarity of actively formation of resistance to new antibacterial drugs. The aim is to describe modern approaches to therapy of ventilator-associated pneumonia causative agent of which is presented by Pseudomonas aureginosa . Materials and methods: An analysis and summing up of results of scientific investigations described in medical publications concerning the issues of therapy of ventilatorassociated pneumonia caused by Pseudomonas aureginosa was done. Conclusions: Despite the development of modern approaches to anti-microbial therapy of ventilator-associated pneumonia caused by Pseudomonas aeruginosa, which are also concerned with such controversial issues as correct choice of antibacterial drug, its optimal dose, and duration of this therapy, the problem of treatment of hospital-acquired infections of respiratory airways caused by Pseudomonas aeruginosa has been discussable yet and requires the further study.
Dissertations / Theses on the topic "Publications on pneumonia"
1
Gründel, Anne, Kathleen Friedrich, Melanie Pfeiffer, Enno Jacobs, and Roger Dumke. "Subunits of the Pyruvate Dehydrogenase Cluster of Mycoplasma pneumoniae Are Surface-Displayed Proteins that Bind and Activate Human Plasminogen." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2015. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-173747.
Full textAbstract:
The dual role of glycolytic enzymes in cytosol-located metabolic processes and in cell surface-mediated functions with an influence on virulence is described for various micro-organisms. Cell wall-less bacteria of the class Mollicutes including the common human pathogen Mycoplasma pneumoniae possess a reduced genome limiting the repertoire of virulence factors and metabolic pathways. After the initial contact of bacteria with cells of the respiratory epithelium via a specialized complex of adhesins and release of cell-damaging factors, surface-displayed glycolytic enzymes may facilitate the further interac-tion between host and microbe. In this study, we described detection of the four subunits of pyruvate dehydrogenase complex (PDHA-D) among the cytosolic and membrane-associated proteins of M.pneumoniae. Subunits of PDH were cloned, expressed and purified to produce specific polyclonal guinea pig antisera. Using colony blotting, fractionation of total proteins and immunofluorescence experiments, the surface localization of PDHA-C was demonstrated. All pecombinant PDH subunits are able to bind to HeLa cells and human plasminogen. These interactions can be specifically blocked by the corresponding polyclon-al antisera. In addition, an influence of ionic interactions on PDHC-binding to plasminogen as well as of lysine residues on the association of PDHA-D with plasminogen was confirmed. The PDHB subunit was shown to activate plasminogen and the PDHB-plasminogen complex induces degradation of human fibrinogen. Hence, our data indicate that the surface-associated PDH subunits might play a role in the pathogenesis of M.pneumoniae infections by interaction with human plasminogen.
2
Feldman, Charles. "Contributions to an understanding of community-acquired pneumonia." Thesis, 2010. http://hdl.handle.net/10539/8612.
Full textBook chapters on the topic "Publications on pneumonia"
1
"A mathematical model for the spread of streptococcus pneumoniae with transmission due to sequence type." In Conference Publications 2011. AIMS Press, 2011. http://dx.doi.org/10.3934/proc.2011.2011.553.
Full text
2
Skinner, H. Catherine W., Malcolm Ross, and Clifford Frondel. "Health Effects of Inorganic Fibers." In Asbestos and Other Fibrous Materials. Oxford University Press, 1989. http://dx.doi.org/10.1093/oso/9780195039672.003.0006.
Full textAbstract:
It has become fashionable to start discussions of disease related to fibrous inorganic materials by referring to Pliny the Younger (A.D. 61-114), who commented in a letter on the sickness of slaves who worked with asbestos. His observation was forgotten, as evidenced by the fact that during the Middle Ages, Paracelsus (1493–1541) as well as Agricola (1494–1556) wrote extensively on “miner’s disease” without mentioning asbestos. Later, Zenker (1867) coined the word pneumo(no)coniosis to describe the diseases endemic to coal and iron miners. Differential diagnosis of the pulmonary disorders, tuberculosis, silicosis, pneumonia, and other lung disease was attempted thereafter, although the varieties were often confused even by experienced physicians. The industry that provided asbestos to modern society started at about this same time (in the 1870s). The first indication of pulmonary disorder in an asbestos worker came in an autopsy report of fibrosis by Dr. Montague- Murray at Charing Cross Hospital, London, in 1899–1900 (Peters and Peters, 1980). By 1902 asbestos was included in the list of dusts considered injurious by the Lady Inspector of Factories, Adelaide Anderson (Oliver, 1902). Auribault (1906) appears to have been the first to note high mortality in workers in an asbestos mill and weaving establishment, but he attributed their illness to calcium carbonate dust rather than asbestos. Scarpa (1908) believed the pulmonary disease of 30 asbestos workers was caused by tuberculosis, and Fahr (1914), who published the case of a female asbestos worker who died of “pleuro-pneumonia . . . with a large number of crystals in pulmonary tissue of a peculiar nature,” was clearly somewhat mystified at the presence of nonbiological materials. It was Cooke (1924, 1927, 1929) who first defined asbestos as a specific etiologic agent in pulmonary fibrosis. He described extensive fibrosis with thickened pleura and adhesions to the chest wall and pericardium in asbestos workers and noted the presence of abundant mineral matter (“curious bodies”), but also tubercular lesions. The term asbestosis was used in the 1927 publication. Pancoast and Pendergrass (1925) argued that the fibrosis seen in asbestos workers was a result of ad-mixed silica and an expression of “asbestosilicosis,” signifying uncertain etiology of the observed symptoms, a view that survivied into the 1930s (Lynch and Smith, 1935).
3
Shin, Gee Yen. "Vaccination Schedules." In Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0062.
Full textAbstract:
The vaccines included in the current UK Immunisation Schedule offer protection against the following pathogens: A. Viruses ● Measles ● Mumps ● Rubella ● Polio ● Human Papilloma Virus (certain serotypes) ● Rotavirus ● Influenza virus (flu A and B) ● Varicella zoster virus (shingles) ● Hepatitis B virus B. Bacteria ● Corynebacterium diphtheriae (Diphtheria) ● Clostridium tetani (Tetanus) ● Bordetella pertussis (Pertussis) ● Haemophilus influenzae type B (Hib) ● Neisseria meningitidis (Meningococcal disease—certain serotypes) ● Streptococcus pneumoniae (Pneumococcal disease—certain serotypes) The UK Immunisation Schedule has evolved over several decades and reflects changes in vaccine development and commercial availability, national and sometimes international disease epidemiology, and the latest expert opinion. It is designed to offer optimal protection against infectious diseases of childhood to infants and children at the most appropriate age. The most up-to-date information about the UK Immunisation Schedule is available on the online version of the Department of Health publication commonly known as the ‘Green Book’: Immunisation Against Infectious Disease Handbook (see Further reading. Various chapters of the online version are updated at regular intervals; thus, it is very important to refer to the online version of the Green Book on the website for current guidance. Changes to the UK Immunisation Schedule are made on the recommendation of the independent Joint Committee on Vaccines and Immunisation (JCVI). Several of the UK Immunisation Schedule vaccines are combined vaccines: ● Measles, mumps, and rubella (MMR). ● Hexavalent diphtheria, tetanus, acellular pertussis, inactivated polio virus, Haemophilus influenza type b, hepatitis B (DTaP/IPV/Hib/HepB). ● Diphtheria, tetanus, acellular pertussis, inactivated polio, and Haemophilus influenzae (DTaP/IPV/Hib). ● Diphtheria, tetanus, acellular pertussis, inactivated polio (DTaP/IPV). ● Tetanus, diphtheria, and inactivated polio (Td/IPV). ● Inactivated influenza vaccine: influenza A H1N1, H3N2, influenza B. ● Live attenuated intranasal influenza vaccine: influenza A H1N1, H3N2, influenza B. In the UK, vaccines against single pathogens covered by the MMR vaccine are not recommended and not available in the National Health Service (NHS). There has been some limited demand for single-target vaccines, e.g. measles, due to misguided and unfounded concerns about the alleged risks of autism following MMR.